Pharmacovigilance is the science and activities related to the detection, assessment, understanding, and prevention of adverse effects or any other drug-related problems. Signal detection is a crucial component of pharmacovigilance, which involves the systematic review of safety data from various sources, including spontaneous reports, clinical trials, literature, and other relevant sources, to identify potential safety concerns or signals.
Signal detection methods typically involve statistical analysis of safety data to identify any unusual patterns or trends that may indicate a potential safety concern. These methods may include disproportionality analysis, Bayesian analysis, time-to-onset analysis, and other statistical techniques.
Once a safety signal is detected, it is then evaluated further to determine the clinical relevance and potential impact on patient safety. This process may involve a detailed analysis of the available data, including clinical trial data, epidemiological studies, and other relevant information.
Aggregate reports are another important component of pharmacovigilance. These reports summarize the safety profile of a drug product based on the available safety data, including adverse event reports, clinical trial data, and other relevant information. Aggregate reports may include periodic safety update reports (PSURs), periodic benefit-risk evaluation reports (PBRERs), and other similar reports.
These reports are typically submitted to regulatory agencies to meet regulatory requirements and provide a comprehensive overview of the safety profile of a drug product. They may also be used internally by pharmaceutical companies to monitor the safety of their products and identify potential safety concerns that require further investigation.
This course will equip you not only to attend all interviews, but also help in confident handling of the on job work giving the candidate a distinct advantage.
View this Course
Certified
You have successfully registered
